Epstein-Barr 病毒(EBV ) 联系了鼻咽的癌(NPC ) 是在东南亚洲的一个高发生肿瘤。在 EBV 之中编码了蛋白质,潜伏的膜蛋白质 2A (LMP2A ) 是为 EBV 的 T 房间治疗的重要抗原。在这研究,我们预言六 HLA-A2 由方法与多项式方法相结合的 SYFPEITHI, NetMHC 和 MHCPred 限制了 LMP2A 的 CTL 候选人 epitopes。随后,这些肽的生物功能被实验在 vitro 测试。在 ELISPOT 试金, LMP2A 特定的 CTL 的积极反应在三刺激了( LMP2A264-272 , LMP2A426-434 和 LMP2A356-364 )六,肽分别地证明形成房间( SFC )的点的数字从 55.7~80.6 SFC/5 104 个CD8+ T 房间和反应索引( RI )从 5.4~7 。这三 epitope 特定的 CTL 能有效地杀死特定的 HLA-A2-expressing 目标房间。作为结果, LMP2A264-272 (QLSPLLGAV ) , LMP2A426-434 (CLGGLLTMV ) 和 LMP2A356-364 (FLYALALLL ) 作为 LMP2A 特定的 CD8+T 房间 epitopes 被识别。向 EBV 澄清有免疫力的反应并且对 EBV 关联词 NPC 开发一支疫苗将是有用的。
Epstein-Barr virus (EBV) associated nasopharyngeal carcinoma (NPC) is a high incidence tumor in Southeast Asia. Among EBV encoded proteins, latent membrane protein 2A (LMP2A) is an important antigen for T cell therapy of EBV. In this study, we predicted six HLA-A2 restricted CTL candidate epitopes of LMP2A by SYFPEITHI, NetMHC and MHCPred methods combined with the polynomial method. Subsequently, biological functions of these peptides were tested by experiments in vitro. In ELISPOT assay, the positive response of the LMP2A specific CTL stimulated by three (LMP2A264.272, LMP2A426-434 and LMP2A3s6.364) of six peptides respectively showed that the numbers of spots forming cells (SFC) ranged from 55.7 to 80.6 SFC/5 x 104 CO8^+ T cells and the responding index (RI) ranged from 5.4 to 7. These three epitope-specific CTLs could effectively kill specific HLA-A2- expressing target cells. As a result, LMP2A264.272 (QLSPLLGAV), LMP2A426.434 (CLGGLLTMV) and LMP2A356.364 (FLYALALLL) were identified as LMP2A-specific CD8^+ T-cell epitopes. It would be useful to clarify immune response toward EBV and to develop a vaccine against EBV-correlative NPC.